Dopamine D1 receptor agonist compounds

A receptor stimulant, dopamine technology, applied in the direction of active ingredients of heterocyclic compounds, organic chemistry, drug combination, etc., can solve problems such as abnormalities
CN1142916CInactive Publication Date: 2004-03-24SHIRE PHARMA DEV
5 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHIRE PHARMA DEV
Publication Date
2004-03-24
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides 2,3,4,5-tetrahydro-1H-3-benzazepines of general formula (I) wherein: R<1> is hydrogen, halogen, C1-C4 alkyl, or CF3; R<2> is hydrogen, methyl, or lower alkenyl of 3-5 carbon atoms; R<3> and R<4> together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R<5> is hydrogen or R<4> and R<5> together form a furan, dihydrofuran, thiophene, dihydrothiophene, cyclopentane or cyclohexane ring and R<3> is hydrogen; R<6> is hydrogen, halogen, CF3, CN, NO2 or NH2; R<7> is hydrogen, halogen, CF3, CN, NO2 or NH2. The specific combination of substituents: R1 = H, R2 = H and R4 and R5 together forming a cyclohexane ring is excluded, namely 1-(5,6,7,8-tetrahydronaphthalen-2-yl)-2,3,4,5-tetrahydro-1H-benzol[d]azepine-7,8-diol. The compounds of the invention provide therapeutic agents that selectively interact positively with postsynaptic dopamine D1 receptors in the striatum, directly or in-directly (termed dopamine D1 agonists) and are particularly valuable as anti-Parkinsonian agents.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to a dopamine D1 receptor stimulant compound, a preparation method and use of the compound. Background technique

[0002] GB 1 599 705 discloses 1-thienyl and 1-furyl-2,3,4,5-tetrahydro-1H-3-benzazepines suitable for use as cardiovascular drugs. Certain benzoacridines have been disclosed as dopamine D1 receptor agonists. For example, 1-phenyl-3-benzazepine is disclosed in EP 0 230 755-A, and 6-chloro-7,8-dihydroxy-1-( Carbamate of 4'-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine.

[0003] The present invention provides compounds that are potent and selective ligands for the dopamine D1 receptor. The compounds are useful in the treatment of neurodegenerative diseases, particularly, but not limited to, Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disease characterized by the progressive death of postsynaptic dopamine neurons in the substantia nigra innervating postsynaptic striatal neu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More